Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK ALK L1196M ALK G1269A |
Therapy | Alectinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK ALK L1196M ALK G1269A | lung adenocarcinoma | predicted - resistant | Alectinib | Case Reports/Case Series | Actionable | In a clinical case study, ALK L1196M and G1269A were identified in post-progression lymph node biopsy with a poorly differentiated adenocarcinoma pathology in a patient with metastatic lung adenocarcinoma and transformed small cell carcinoma harboring EML4-ALK, who previously achieved a partial response on Alecensa (alectinib) treatment (PMID: 38961982). | 38961982 |
PubMed Id | Reference Title | Details |
---|---|---|
(38961982) | Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report. | Full reference... |